Orlance Inc. Awarded Pivotal $3M NIH SBIR Grant for Advancing MACH-1™ Needle-Free, Powdered Universal Influenza Vaccine to the Clinic

/PRNewswire/ -- Orlance, Inc., a Seattle biotech developing next-generation DNA and RNA vaccines and therapeutics, has been awarded a three-year $3M National...

Related Keywords

Hannah Frizzell ,Kristyn Aalto ,Um National Institutes Of Health ,Phase Ii Small Business Innovation Research ,University Of Washington ,University Of Washington School Medicine ,Prnewswire Orlance Inc ,National Institutes ,Business Innovation Research ,Deborah Fuller ,Washington School ,Orlance ,